Dr. Reddy's Laboratories (RDY) said Wednesday it received a Notice of Compliance from Health Canada to market its generic semaglutide injection.
The regulatory clearance makes the pharmaceutical manufacturer the first company to obtain approval for the type 2 diabetes treatment in the country, the company said.
The authorization covers the 2 mg and 4 mg pen dosages and was granted ahead of the agency's target review date, it said.
Shares of the company were down 1.9% in Wednesday trading.
Price: 13.77, Change: -0.26, Percent Change: -1.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments